

Substitute for form 1449A-PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

10/714,255

Filing Date

November 14, 2003

First Named Inventor

Carlo BALLATORE

Art Unit

1623

Examiner Name

Not Yet Assigned

Attorney Docket Number

NB 2020.01

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number – Kind Code ² (if known) | Publication Date MM-DD-YY | Name of Patentee or Application of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|------------------------------|--|---|
| Ro | 1 | US-4,053,638 | 10-11-77 | Litchfield et al. | |
| Ro | 2 | US-4,083,974 | 04-11-87 | Turi | |
| Ro | 3 | US-4,339,440 | 07-13-82 | Bajusz et al. | |
| Ro | 4 | US-5,918,568 | 07-06-99 | Gjerlov | |
| Ro | 5 | US-6,110,908 | 08-29-00 | Guthery | |
| Ro | 6 | US-6,143,790 | 11/07/00 | Hallinan et al. | |
| Ro | 7 | US-6,448,058 B1 | 09-10-02 | Patel et al. | |
| Ro | 8 | US-6,613,879 B1 | 09-02-03 | Firestone et al. | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known) | Publication Date MM-DD-YY | Name of Patentee or Application of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|------------------------------|---|---|----------------|
| Ro | 9 | WO 02/089739 A2 | 11-14-02 | NewBiotics, Inc. | | |
| Ro | 10 | WO 03/088913 A2 | 10-30-03 | NewBiotics, Inc. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Examiner's
Signature

R. Desai

Date
Considered


5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 10/714,255 |
| Filing Date | November 14, 2003 |
| First Named Inventor | Carlo BALLATORE et al. |
| Art Unit | 1623 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | NB 2020.01 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YY | Name of Patentee or Application of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|------------------------------|--|---|
| | | Number - Kind Code ² (if known) | | | |
| RD | 1 | US-6,159,706 | 12-12-2000 | Shepard | |
| RD | 2 | US-6,245,750 | 06-12-2001 | Shepard | |
| RD | 3 | US-6,339,151 | 01-15-2002 | Shepard et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YY | Name of Patentee or Application of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|------------------------------|---|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| RD | 4 | WO 99/08110 | 02-18-1999 | NewBiotics, Inc. | | |
| RD | 5 | WO 99/37753 | 07-29-1999 | NewBiotics, Inc. | | |
| RD | 6 | WO 01/07454 A1 | 02-01-2001 | NewBiotics, Inc. | | |
| RD | 7 | WO 98/13059 A | 04-02-1998 | Squibb Bristol Myers | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Examiner's
Signature

RD Desai

Date
Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 10/714,255 |
| Filing Date | November 14, 2003 |
| First Named Inventor | Carlo BALLATORE, et al. |
| Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | NB 2020.01 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| | 1 | APFEL, C. et al. "Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents" (2000) <i>J. Med. Chem.</i> 43:2324-2331 | |
| | 2 | APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in <i>escherichia coli</i> cell homogenates and intact cells" (April, 2001a) <i>Anti. Agents and Chemo.</i> 45(4):1053-1057 | |
| | 3 | APFEL, C.M. et al. "Peptide deformylase as an antibacterial drug target: Target validation and resistance development" (April, 2001b) <i>Anti. Agents and Chemo.</i> 45(4):1058-1064 | |
| | 4 | BECKER, A. et al. "Iron center, substrate recognition and mechanism of peptide deformylase" (1998) <i>Nat. Struct. Biol.</i> 5(12):1053-1058 | |
| | 5 | CHAN, Michael K. et al. "Crystal structure of the <i>escherichia coli</i> peptide deformylase" <i>Biochem.</i> (1997) 36:13904-13909 | |
| | 6 | CHEN, D.Z. et al. "Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor" (2000) <i>Biochem.</i> 39(6):1256-1262 | |
| | 7 | CLEMENTS, J.M. et al. "Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor" (February, 2001) <i>Anti. Agents and Chemo.</i> 45(2):563-570 | |
| | 8 | de GROOT, F.M.H. et al. "Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin" (2000) <i>J. Med. Chem.</i> 43:3093-3102 | |
| | 9 | DUBOWCHICK, G.M. et al. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin, <i>Bioorg & Medicinal Chem. Letters</i> 8(23):3341-3346. | |
| | 10 | DURAND, D.J. et al. "Peptide deformylase inhibitors of bacterial peptide deformylases" (July 15, 1999) <i>Arch. Biochem. And Biophysics.</i> 367(2): 297-302 | |
| | 11 | GIGLIONE, C. et al. "Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents" (2000a) <i>Mol. Microbiol.</i> 36(6):1197-1205 | |
| | 12 | GIGLIONE, C. et al. "Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms" <i>EMBO J.</i> (2000b) 19(21):5916-5929 | |
| | 13 | HAO, B. et al. "Structural basis for the design of antibiotics targeting peptide deformylase" (1999) <i>Biochem.</i> 38(15):4712-4719 | |
| | 14 | HU, Y.J. et al. "H-phosphonate derivatives as novel peptide deformylase inhibitors" (1998) <i>Bioorg Med Chem Letts.</i> 8(18):2479-2482 | |
| | 15 | HUNTINGTON, K.M. et al. "Synthesis and antibacterial activity of peptide deformylase inhibitors" (2000) <i>Biochem.</i> 39(15):4543-4551 | |
| | 16 | JAYASEKERA, M.M.K. et al. "Novel nonpeptidic inhibitors of peptide deformylase" (Sept. 15, 2000) <i>Arch. Biochem. & Biophys.</i> 381(2):313-316 | |
| | 17 | LACKEY, D.B. et al. (2001) Enzyme - catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB 1011 by thymidylate synthase, <i>Biochem. Pharmacology</i> 61:179-189 | |
| | 18 | MEINNEL, T. "Vers une conception rationnelle de nouveaux agents antibactériens" (1999) <i>Pathol. Biol.</i> 47(8):780-783 | |

Examiner's
Signature

Roderer

Date
Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 2 | of | 2 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|--------------------------------|
| Application Number | 10/714,255 |
| Filing Date | November 14, 2003 |
| First Named Inventor | Carlo BALLATORE, et al. |
| Art Unit | 1623 |
| Examiner Name | Unassigned |
| Attorney Docket Number | NB 2020.01 |

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner's
Signature**

Date
Considered

5/5/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.